Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach

Table 2

The most promising MHC class I-related peptides in the envelope protein-based vaccine of COVID-19 along with the predicted coverage of the world, China, Europe, and East Asia.

Peptide	Alleles	Coverage	Combined coverage of 10 peptides
YVYSRVKNL	HLA-C14:02, HLA-C12:03, HLA-C07:01, HLA-C03:03, HLA-C06:02	50.02%	World: 88.5%
SLVKPSFYV	HLA-A02:06, HLA-A02:01, HLA-A68:02	42.53%	China: 78.17%
SVLLFLAFV	HLA-A02:06, HLA-A68:02, HLA-A02:01	42.53%	Europe: 92.94%
FLAFVVFLL	HLA-A02:01, HLA-A02:06	40.60%	East Asia: 80.78%
VLLFLAFVV	HLA-A02:01	39.08%
RLCAYCCNI	HLA-A02:01	39.08%
FVSEETGTL	HLA-C03:03, HLA-C12:03, HLA-A02:06, HLA-A68:02, HLA-B35:01	28.22%
LTALRLCAY	HLA-A01:01, HLA-A30:02, HLA-B15:01	26.34%
LVKPSFYVY	HLA-B15:01, HLA-A29:02, HLA-A30:02, HLA-B35:01	21.72%
NIVNVSLVK	HLA-A68:01, HLA-A11:01	20.88%